By Krishna N. Das
NEW DELHI (Reuters) – Indian pharmaceutical company Biological E Ltd is looking to contract-manufacture roughly 600 million doses of Johnson and Johnson’s COVID-19 vaccine candidate annually, Mahima Datla, managing director of the privately-held company said on Wednesday.
“We are targeting 600 million doses for J&J,” said Datla. “This will be in addition to our own product for which we are targeting approximately 1 billion doses.”
(Reporting by Krishna N. Das; Editing by Euan Rocha)
